Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

PRTK | Paratek Pharmaceuticals Inc.

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	16.38%	Shs Outstand	56.65M	Perf Week	1.36%
Market Cap	127.82M	Forward P/E	111.50	EPS next Y	0.02	Insider Trans	7.39%	Shs Float	47.93M	Perf Month	2.53%
Income	-62.73M	PEG	-	EPS next Q	-0.25	Inst Own	51.53%	Short Float / Ratio	5.50% / 3.96	Perf Quarter	0.90%
Sales	177.00M	P/S	0.72	EPS this Y	9.92%	Inst Trans	-	Short Interest	2.64M	Perf Half Y	19.89%
Book/sh	-3.52	P/B	-	EPS next Y	-	ROA	-40.54%	Target Price	3.10	Perf Year	-10.80%
Cash/sh	0.75	P/C	2.99	EPS next 5Y	-	ROE	-	52W Range	1.29 - 3.65	Perf YTD	19.25%
Dividend	-	P/FCF	-	EPS past 5Y	18.84%	ROI	-	52W High	-38.90%	Beta	1.67
Dividend %	-	Quick Ratio	0.46	Sales past 5Y	83.30%	Gross Margin	85.53%	52W Low	72.87%	ATR	0.02
Employees	268	Current Ratio	0.52	Sales Q/Q	34.94%	Oper. Margin	-25.17%	RSI (14)	59.19	Volatility	1.26% 1.07%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	23.53%	Profit Margin	-35.44%	Rel Volume	0.00	Prev Close	2.23
Shortable	No	LT Debt/Eq	-	Earnings	Aug 03 BMO	Payout	-	Avg Volume	664.81K	Price	2.23
Recom	2.33	SMA20	1.27%	SMA50	1.53%	SMA200	8.23%	Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
May-02-23	Resumed	Jefferies	Buy	$7 → $5
Apr-17-23	Resumed	BTIG Research	Buy	$24
Feb-10-22	Upgrade	WBB Securities	Buy → Strong Buy	$11
Apr-23-21	Upgrade	WBB Securities	Speculative Buy → Buy	$6 → $10
Mar-02-21	Initiated	Jefferies	Buy	$15
Nov-09-20	Reiterated	H.C. Wainwright	Buy	$19 → $22
Jan-08-20	Initiated	WBB Securities	Speculative Buy	$6
Jan-02-19	Initiated	Canaccord Genuity	Buy	$14
Nov-23-18	Reiterated	H.C. Wainwright	Buy	$55 → $22
Aug-27-18	Initiated	BofA/Merrill	Neutral	$13
Mar-02-18	Downgrade	Raymond James	Strong Buy → Outperform
Oct-24-17	Initiated	Guggenheim	Buy	$44
Jul-18-17	Reiterated	H.C. Wainwright	Buy	$36 → $43
May-19-17	Initiated	Raymond James	Strong Buy
Apr-11-17	Reiterated	H.C. Wainwright	Buy	$33 → $36
Apr-04-17	Reiterated	Wedbush	Outperform	$30 → $34
Apr-04-17	Initiated	Wedbush	Outperform	$30
Oct-27-16	Resumed	Leerink Partners	Outperform	$23
Jun-17-16	Reiterated	H.C. Wainwright	Buy	$31 → $34
May-13-16	Initiated	Robert W. Baird	Outperform	$30

Show Previous Ratings

Sep-21-23 12:26PM	CORRECTED-Novo Holdings, Gurnet Point close $462 mln acquisition of Paratek Pharmaceuticals (Reuters)
08:58AM	Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc. (GlobeNewswire)
Sep-18-23 09:37AM	Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S (GlobeNewswire)
Sep-12-23 07:30AM	Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S (GlobeNewswire)
Sep-07-23 03:34PM	Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings (GlobeNewswire)
02:37PM	Loading…
Aug-04-23 02:37PM	News Flash: Analysts Just Made A Captivating Upgrade To Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Forecasts (Simply Wall St.)
Aug-03-23 09:15AM	Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:13AM	Paratek: Q2 Earnings Snapshot (AP Finance)
08:00AM	Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million (GlobeNewswire)
Aug-02-23 05:36PM	Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings (GlobeNewswire)
Jul-17-23 09:05PM	argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains? (Zacks)
Jul-11-23 04:15PM	NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital (PR Newswire)
Jul-10-23 08:00AM	Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax (GlobeNewswire)
Jun-27-23 12:01PM	Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter (GlobeNewswire)
08:00AM	NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital (PR Newswire)
08:00AM	Loading…
08:00AM	European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease (GlobeNewswire)
Jun-12-23 08:00AM	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023 (GlobeNewswire)
Jun-06-23 09:05AM	Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings (GlobeNewswire) +10.71%
May-15-23 11:26AM	Paratek Pharmaceuticals (NASDAQ:PRTK) investors are sitting on a loss of 83% if they invested five years ago (Simply Wall St.)
May-10-23 03:31PM	7 Growth Stocks That Are Too Cheap to Ignore Right Now (InvestorPlace) +10.65%
10:59AM	Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q1 2023 Earnings Call Transcript (Insider Monkey)
06:23AM	Q1 2023 Paratek Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-23 05:45PM	Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.11%
04:38PM	Paratek: Q1 Earnings Snapshot (AP Finance)
04:05PM	Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million (GlobeNewswire)
May-01-23 08:30AM	Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9 (GlobeNewswire)
Apr-17-23 06:13AM	There's No Escaping Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Muted Revenues Despite A 77% Share Price Rise (Simply Wall St.)
Apr-10-23 07:30AM	Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023 (GlobeNewswire)
Mar-18-23 02:03AM	Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 10:12PM	Q4 2022 Paratek Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -22.51%
03:11PM	Loading…
03:11PM	Why Paratek Pharmaceuticals Stock Is Plunging Today (Benzinga)
08:55AM	Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million (GlobeNewswire)
Mar-08-23 08:30AM	Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16 (GlobeNewswire) -5.32%
Mar-01-23 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-23-23 10:52AM	Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) On The Verge Of Breaking Even (Simply Wall St.)
Feb-01-23 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-23 07:00AM	Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in Chinas National Reimbursement Drug List (NRDL) (GlobeNewswire) -8.19%
Jan-05-23 08:00AM	Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract (GlobeNewswire) +11.22%
Jan-02-23 10:50AM	Individual investors account for 39% of Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) ownership, while institutions account for 38% (Simply Wall St.)
Dec-20-22 07:30AM	Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board (GlobeNewswire)
Dec-19-22 07:30AM	Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield (GlobeNewswire) +6.74%
Dec-01-22 05:45PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-22 04:05PM	Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-09-22 05:32AM	Paratek Pharmaceuticals Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-03-22 05:45PM	Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million (GlobeNewswire)
Nov-01-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-31-22 08:00AM	Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract (GlobeNewswire)
Oct-25-22 08:00AM	Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3 (GlobeNewswire) +6.93%
Oct-13-22 04:05PM	Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022 (GlobeNewswire)
Oct-03-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-26-22 08:30AM	Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM) (GlobeNewswire)
Sep-16-22 11:12AM	Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Is Expected To Breakeven In The Near Future (Simply Wall St.) +6.50%
Sep-01-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-04-22 01:30AM	Paratek Pharmaceuticals (PRTK) Q2 2022 Earnings Call Transcript (Motley Fool)
Aug-03-22 05:25PM	Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:30PM	Edited Transcript of PRTK.OQ earnings conference call or presentation 3-Aug-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million (GlobeNewswire)
Aug-01-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-25-22 04:05PM	Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022 (GlobeNewswire)
Jul-18-22 09:32AM	Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jul-01-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-21-22 04:05PM	Paratek Pharmaceuticals NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycobacterium Abscessus (MAB) (GlobeNewswire) +5.00%
Jun-08-22 07:10AM	Even after rising 25% this past week, Paratek Pharmaceuticals (NASDAQ:PRTK) shareholders are still down 89% over the past five years (Simply Wall St.)
Jun-01-22 04:15PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference (GlobeNewswire)
May-16-22 04:05PM	Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-05-22 12:30PM	Paratek Pharmaceuticals (PRTK) Q1 2022 Earnings Call Transcript (Motley Fool)
May-04-22 04:05PM	Paratek Pharmaceuticals Announces First Quarter 2022 Revenue of $24.9 Million (GlobeNewswire)
May-02-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-26-22 04:05PM	Paratek Pharmaceuticals to Report First Quarter 2022 Financial Results on May 4, 2022 (GlobeNewswire) -5.17%
Apr-09-22 10:49AM	Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK) Profit Outlook (Simply Wall St.)
Apr-01-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-14-22 12:30PM	Paratek Pharmaceuticals (PRTK) Q4 2021 Earnings Call Transcript (Motley Fool) -7.33%
07:30AM	Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million (GlobeNewswire)
Mar-08-22 04:05PM	Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA® (omadacycline) in a Hollow Fiber System Model Against Pulmonary Mycobacterium avium complex (GlobeNewswire)
Mar-02-22 04:05PM	Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, 2022 (GlobeNewswire)
Mar-01-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member (GlobeNewswire)
Feb-08-22 09:36AM	What Is The Ownership Structure Like For Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK)? (Simply Wall St.)
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com)
Feb-01-22 09:38PM	AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ... (GuruFocus.com) +6.42%
04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-22 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-16-21 11:36AM	China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections (GlobeNewswire) +5.39%
Dec-10-21 08:36AM	Investors in Paratek Pharmaceuticals (NASDAQ:PRTK) from five years ago are still down 67%, even after 11% gain this past week (Simply Wall St.)
Dec-05-21 03:30AM	Options Play of the Week: Paratek Pharmaceuticals (TheStreet.com)
Dec-01-21 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-21 04:05PM	Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference (GlobeNewswire)
Nov-08-21 06:05PM	Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021 (GlobeNewswire)
Nov-01-21 04:05PM	Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021 (GlobeNewswire)
04:04PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-28-21 03:05PM	Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline (Zacks)
Oct-18-21 04:05PM	Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) (GlobeNewswire)
Oct-11-21 01:11PM	When Will Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Turn A Profit? (Simply Wall St.)
Oct-01-21 04:05PM	Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loh Evan	CEO	Aug 09	Sale	2.20	48,967	107,727	1,327,981	Aug 10 08:26 PM
Haskel William M.	CLO, General Counsel & Sec.	Aug 09	Sale	2.20	34,526	75,957	447,024	Aug 10 08:32 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Aug 09	Sale	2.20	31,250	68,750	1,334,702	Aug 10 08:35 PM
Brenner Randall B.	Chief Development & Regulatory	Aug 09	Sale	2.20	27,603	60,727	415,209	Aug 10 08:38 PM
DONDERO JAMES D	10% Owner	Mar 23	Buy	1.73	100,000	173,000	2,156,000	Mar 29 04:31 PM
DONDERO JAMES D	10% Owner	Mar 22	Buy	1.77	106,000	187,620	2,056,000	Mar 29 04:31 PM
DONDERO JAMES D	10% Owner	Mar 21	Buy	1.74	242,500	421,950	1,307,617	Mar 29 04:31 PM
DONDERO JAMES D	10% Owner	Mar 20	Buy	1.40	105,137	147,192	2,239,770	Mar 29 04:31 PM
DONDERO JAMES D	10% Owner	Mar 17	Buy	1.50	234,863	352,294	2,134,663	Mar 29 04:31 PM
Stein Jeffrey	Director	Feb 21	Sale	1.90	7,000	13,300	68,625	Feb 23 02:27 PM
Franson Timothy R	Director	Feb 21	Sale	1.88	7,000	13,160	72,000	Feb 23 02:22 PM
Loh Evan	CEO	Dec 21	Sale	1.99	23,489	46,743	1,208,198	Dec 22 04:44 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Dec 21	Sale	1.99	15,750	31,342	1,209,702	Dec 22 04:26 PM
Haskel William M.	CLO, General Counsel & Sec.	Dec 21	Sale	1.99	7,007	13,944	407,800	Dec 22 04:38 PM
Woodrow Adam	President & Chief Commercial	Dec 21	Sale	1.99	6,750	13,432	651,284	Dec 22 04:51 PM
Brenner Randall B.	Chief Development & Regulatory	Dec 21	Sale	1.99	4,539	9,033	335,312	Dec 22 04:33 PM
Loh Evan	CEO	Dec 13	Sale	1.96	61,919	121,361	1,179,187	Dec 14 08:08 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Dec 13	Sale	1.96	31,891	62,506	1,180,452	Dec 14 08:00 PM
Haskel William M.	CLO, General Counsel & Sec.	Dec 13	Sale	1.96	23,584	46,225	399,807	Dec 14 08:05 PM
Brenner Randall B.	Chief Development & Regulatory	Dec 13	Sale	1.96	18,177	35,627	324,851	Dec 14 08:03 PM
Woodrow Adam	President & Chief Commercial	Dec 13	Sale	1.96	6,253	12,256	635,534	Dec 14 08:11 PM
Loh Evan	CEO	Dec 12	Sale	1.98	37,831	74,905	1,241,106	Dec 14 08:08 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Dec 12	Sale	1.98	19,484	38,578	1,212,343	Dec 14 08:00 PM
Haskel William M.	CLO, General Counsel & Sec.	Dec 12	Sale	1.98	14,410	28,532	423,391	Dec 14 08:05 PM
Brenner Randall B.	Chief Development & Regulatory	Dec 12	Sale	1.98	11,105	21,988	343,028	Dec 14 08:03 PM
Woodrow Adam	President & Chief Commercial	Dec 12	Sale	1.98	3,820	7,564	641,787	Dec 14 08:11 PM
Loh Evan	CEO	Oct 28	Sale	3.47	8,805	30,553	1,278,937	Nov 01 07:58 PM
BIGHAM MICHAEL	Exec. Chairman of the Board	Oct 28	Sale	3.47	6,000	20,820	1,231,827	Nov 01 07:51 PM
Woodrow Adam	President & Chief Commercial	Oct 28	Sale	3.47	4,563	15,834	645,607	Nov 01 08:00 PM
Haskel William M.	CLO, General Counsel & Sec.	Oct 28	Sale	3.47	4,382	15,206	437,801	Nov 01 07:55 PM
Brenner Randall B.	Chief Development & Regulatory	Oct 28	Sale	3.47	3,516	12,201	354,133	Nov 01 07:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PRTK | Paratek Pharmaceuticals Inc.

Upgrade your FINVIZ experience